- Home
- WEX vs LEGN Comparison
WEX vs LEGN Comparison
Compare WEX & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WEX | LEGN |
|---|---|---|
| Founded | 1983 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.9B |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WEX | LEGN |
|---|---|---|
| Price | $153.07 | $22.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | ★ $172.92 | $69.58 |
| AVG Volume (30 Days) | 329.8K | ★ 2.3M |
| Earning Date | 02-04-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.64 | N/A |
| Revenue | ★ $2,624,500,000.00 | $909,045,000.00 |
| Revenue This Year | $1.74 | $68.52 |
| Revenue Next Year | $4.34 | $48.63 |
| P/E Ratio | $20.05 | ★ N/A |
| Revenue Growth | N/A | ★ 74.75 |
| 52 Week Low | $110.45 | $21.19 |
| 52 Week High | $188.70 | $45.30 |
Technical Indicators
Market Signals| Indicator | WEX | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 55.24 | 33.52 |
| Support Level | $149.03 | $21.19 |
| Resistance Level | $155.40 | $23.24 |
| Average True Range (ATR) | 3.52 | 1.04 |
| MACD | 0.16 | 0.18 |
| Stochastic Oscillator | 48.90 | 21.26 |
Price Performance
Historical ComparisonAbout WEX WEX Inc. common stock
WEX Inc is a provider of corporate payment solutions. The company operates three business segments: Mobility, Benefits, and Corporate Payments. Mobility segment, the top segment by revenue, provides fleet vehicle payment solutions, transaction processing, and information management services for commercial and government fleets. The Corporate Payments segment offers business-to-business payment processing and transaction monitoring services. The Benefits segment generates revenue from healthcare payment products and its consumer-directed software platform. The company's prime end market is the United States of America.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.